Sarah Petty, APRN
Family · Murray, KYNPI 1093361271
Payments from drug & device makers
Across 220 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$583
- Novo Nordisk$467
- Lilly USA, LLC$443
- Bayer$353
- Novartis$265
- AstraZeneca$243
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,451100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $583 |
| Novo Nordisk | 35 | $467 |
| Lilly USA, LLC | 33 | $443 |
| Bayer | 23 | $353 |
| Novartis | 15 | $265 |
| AstraZeneca | 5 | $243 |
| Boehringer Ingelheim | 11 | $156 |
| Axsome Therapeutics, Inc. | 6 | $124 |
| Si-bone, Inc. | 1 | $105 |
| Pfizer | 6 | $93 |
| Amgen | 6 | $79 |
| Astellas Pharma US Inc | 5 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $70 |
| Sumitomo Pharma America, Inc. | 5 | $57 |
| Johnson & Johnson | 4 | $57 |
| GSK | 3 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Exact Sciences | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Philips North America LLC | 1 | $13 |
| Harmony Biosciences LLC | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
| Genentech USA, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,451 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 103 | $100,405 |
| OzempicSemaglutide | 75 | $73,023 |
| EliquisApixaban | 55 | $54,003 |
| FarxigaDapagliflozin Propanediol | 27 | $30,637 |
| XareltoRivaroxaban | 24 | $29,862 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $28,523 |
| TrulicityDulaglutide | 16 | $22,828 |
| MounjaroTirzepatide | 17 | $17,849 |
| Repatha SureclickEvolocumab | 23 | $12,422 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $10,894 |
| LinzessLinaclotide | 14 | $10,442 |
| Spiriva RespimatTiotropium Bromide | 15 | $10,017 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $9,420 |
| EntrestoSacubitril/Valsartan | 12 | $8,049 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $4,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $156 | $119,841138 claims |
| Novo NordiskOzempic | $467 | $73,02375 claims |
| PfizerEliquis | $93 | $54,00355 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $243 | $41,53041 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $443 | $40,67733 claims |
| Johnson & JohnsonXarelto | $57 | $29,86224 claims |
| GSKTrelegy Ellipta | $49 | $28,52337 claims |
| AbbVieLinzess, Armour Thyroid | $583 | $11,37328 claims |
| NovartisEntresto | $265 | $8,04912 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $37 | $4,90814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.
Other family in Murray
- Margaret NorsworthyMurray$22K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.